Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 200 Day Moving Average – Here’s Why

Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.90 and traded as low as $0.85. Seres Therapeutics shares last traded at $0.88, with a volume of 1,720,972 shares traded.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. StockNews.com downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Seres Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Down 1.1 %

The company has a market capitalization of $150.30 million, a price-to-earnings ratio of -3.83 and a beta of 2.07. The stock’s 50-day simple moving average is $0.79 and its two-hundred day simple moving average is $0.90.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Virtu Financial LLC boosted its holdings in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC increased its position in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Seres Therapeutics during the second quarter worth approximately $64,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics during the 2nd quarter worth $92,000. Finally, State Street Corp grew its holdings in shares of Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.